San Francisco startup Framework Therapeutics is also engaged on an oral, the moment-daily GLP-one drug called GSBR-1290—the drug surpassed Wall Street’s anticipations in June any time a mid-phase study showed regular weight loss of close to 6% and it plans to get started on An additional mid-phase trial towards the top of this calendar year—t